CERO THERAPEUTICS HOLDINGS, INC. Share-based Payment Arrangement, Expense
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Share-based Payment Arrangement, Expense of $1.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-14
- CERO THERAPEUTICS HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.12M, a 512.06% increase year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.62M, a 430.41% increase year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $259.67K.
- CERO THERAPEUTICS HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $348.12K, a 1640.58% increase year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2025 was $1.10M.
- CERO THERAPEUTICS HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2023 was $96.90K.
| Period end | Share-based Payment Arrangement, Expense 2 month | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 5 month | Share-based Payment Arrangement, Expense 5 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 8 month | Share-based Payment Arrangement, Expense 8 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 11 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.12M 10-Q · filed 2026-08-14 | $2.74M 10-Q · filed 2026-08-14 | $3.00M derived: sum of 3 quarters · filed 2026-08-14 | $3.35M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2026-03-31 | $1.62M 10-Q · filed 2026-05-15 | $1.88M derived: sum of 2 quarters · filed 2026-05-15 | $2.23M derived: sum of 3 quarters · filed 2026-05-15 | $2.41M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-12-31 | $259.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $607.78K derived: sum of 2 quarters · filed 2026-04-15 | $791.11K derived: sum of 3 quarters · filed 2026-08-14 | $1.10M 10-K · filed 2026-04-15 | ||||||
| 2025-09-30 | $348.12K 10-Q · filed 2025-11-19 | $531.44K derived: sum of 2 quarters · filed 2026-08-14 | $836.39K 10-Q · filed 2025-11-19 | |||||||
| 2025-06-30 | $183.33K 10-Q · filed 2026-08-14 | $488.27K 10-Q · filed 2026-08-14 | ||||||||
| 2025-03-31 | $304.95K 10-Q · filed 2026-05-15 | |||||||||
| 2024-12-31 | $924.67K 10-K · filed 2026-04-15 | |||||||||
| 2024-09-30 | $20.00K 10-Q/A · filed 2024-11-20 | $430.00K derived: sum of 2 quarters · filed 2024-11-20 | $1.90M 10-Q · filed 2025-11-19 | $1.90M 10-Q/A · filed 2024-11-20 | ||||||
| 2024-06-30 | $30.00K 10-Q · filed 2024-08-14 | $1.49M 10-Q · filed 2025-08-22 | $1.50M 10-Q · filed 2024-08-14 | |||||||
| 2024-03-31 | $90.00K 10-Q · filed 2025-05-15 | |||||||||
| 2023-12-31 | $16.90K derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-04-15 | $36.90K derived: sum of 2 quarters · filed 2025-04-15 | $1.44M derived: sum of 3 quarters · filed 2025-04-15 | $96.90K 10-K · filed 2025-04-15 | ||||||
| 2023-09-30 | $20.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-11-20 | $1.42M derived: sum of 2 quarters · filed 2024-11-20 | $80.00K 10-Q/A · filed 2024-11-20 | |||||||
| 2023-06-30 | $1.40M 10-Q · filed 2024-08-14 | $60.00K 10-Q · filed 2024-08-14 | ||||||||
| 2023-03-31 | $28.14K 10-Q · filed 2024-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |